Clinical Trial Update: Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating long-term safety and efficacy of UX007 in Glucose Transporter Type 1 Deficiency Syndrome (GLUT1 DS) was terminated; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucose Transporter Type Deficiency Syndrome

Drugs mentioned

• UX007 (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Glucose Transporter Type 1 Deficiency Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2020-04-30